Treatment of in-Stent Restenosis by Paclitaxel Coated PTCA Balloons (PACCOCATH - ISR II)

Inclusion Criteria: * Age \> 18 years * Clinical evidence of stable or unstable angina or a positive functional study * Single, restenotic lesion in a stented coronary artery (allowed are multiple lesions but only the target lesion is amenable for percutaneous intervention, i.e. no 'staged' procedures involving non-target lesions) * Diameter stenosis \> 70% (visual estimate) * Stented segment length \< 30 mm * Vessel diameter =\> 2.5 mm * Female patients can enter this study if they are post-menopausal for at least two years or have undergone hysterectomy or sterilization * Signed patient informed consent form * Patients and treating physicians agree that the patient will return for all required post procedure follow-up assessments as defined in the clinical protocol Exclusion Criteria: * Left ventricular ejection fraction of \< 30% * Target lesion/vessel with any of the following characteristics: Clear angiographic calcification in the target lesion or greater than mild calcification in the proximal vessel (minimally radiopaque densities that are discrete and non-linear). Visible thrombus proximal to the lesion. * Known hypersensitivity or contraindication to aspirin, heparin, clopidogrel, abciximab, paclitaxel, or a sensitivity to contrast media which cannot be adequately pre-medicated. * Other medical illness (i.e. cancer, liver disease or congestive heart failure) that may require cytostatic or radiation therapy causing the subject to be non-compliant with the protocol, confound the data interpretation or is associated with limited life-expectancy (i.e., less than two years). * Severe chronic renal insufficiency. * Significant gastrointestinal (GI) bleed within the past six months. History of bleeding diathesis or coagulopathy or will refuse blood transfusions. * Extensive peripheral vascular disease that precludes safe 6 French sheath insertion and/or requires additional anti-platelet and/or anti-coagulation treatment. * Participating in another device or drug study within the last 6 months